Boehringer Ingelheim’s Vetmedin receives expanded label update

Boehringer Ingelheim has announced that the licence for Vetmedin, a treatment for dogs with asymptomatic mitral valve disease (MVD), is being expanded to include new clinical trial data.

The EPIC study, which marked the largest and most cutting-edge study in veterinary cardiology, demonstrated that Vetmedin is able to delay the onset of heart failure for dogs with asymptomatic MVD.

With the drug delivering an average of 15 months of additional symptom-free time as well as extending overall survival, the worldwide study was terminated early to ensure that dogs in the placebo group could also receive the treatment.

Vetmedin represents the only medication licensed to treat asymptomatic MVD in dogs, with the extra symptom-free time it provides accounting for almost ten percent of a dog's lifetime on average.

Panny Morgan, Vetmedin brand manager at Boehringer Ingelheim, said: "Prescribing Vetmedin to dogs with an MVD murmur and enlarged heart will not only extend a dog's lifespan, but it will also have a major impact on their quality of life."

With over 20 years of experience within the animal health market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current animal health roles we have available, you can search for the latest job roles, register your details, or contact the team today.